Forms a Wholly-Owned Subsidiary, Convergen Biotech, Inc., to Focus Diabetes Program Development The licensed technologies are based on the same general gene therapy approach under Genprex's original ...
Health systems learn why cell and gene therapy success depends on workflows, staffing, and finances—not just science—and how to build them.
LEXINGTON, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it has decided to ...
AUSTIN, Texas , Dec. 15, 2022 /PRNewswire/ -- Genprex, Inc. (GNPX) ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for ...
With gene editing widely touted as the future of agricultural biotechnology, seed trait developers are looking for ways to show they are using the technology responsibly. The latest move is the ...
First patient dosed in REVEAL pivotal trial evaluating TSHA-102 (N=15, aged 6 to <22 years) in Q4 2025, with enrollment advancing across multiple sites Reached written alignment with FDA on inclusion ...
BOSTON & CAMBRIDGE, England--(BUSINESS WIRE)--Broken String Biosciences (“Broken String”), a leader in advancing gene editing safety, today opened its Catalyst Early Access Program (EAP) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results